Cabot Wealth Management Inc. Buys 2,247 Shares of Zoetis Inc. (NYSE:ZTS)

Cabot Wealth Management Inc. increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 3.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 62,483 shares of the company’s stock after acquiring an additional 2,247 shares during the period. Cabot Wealth Management Inc.’s holdings in Zoetis were worth $10,180,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in ZTS. Pensionfund Sabic lifted its holdings in shares of Zoetis by 55.6% in the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after purchasing an additional 4,000 shares in the last quarter. Callahan Advisors LLC raised its position in Zoetis by 90.4% in the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock valued at $2,135,000 after buying an additional 6,221 shares during the last quarter. PFW Advisors LLC bought a new stake in Zoetis in the 4th quarter valued at approximately $1,764,000. CIBC Asset Management Inc boosted its position in Zoetis by 24.1% during the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock worth $38,617,000 after acquiring an additional 46,050 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Zoetis by 10.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock worth $569,834,000 after acquiring an additional 279,092 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Performance

ZTS opened at $160.39 on Friday. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The stock has a market cap of $71.82 billion, a price-to-earnings ratio of 29.32, a PEG ratio of 2.78 and a beta of 0.90. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.53. The business has a 50 day moving average of $166.51 and a 200-day moving average of $177.99.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The firm had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, equities research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.25%. Zoetis’s dividend payout ratio is currently 36.56%.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of research reports. Stifel Nicolaus cut their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Leerink Partners began coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Piper Sandler dropped their target price on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. Finally, UBS Group initiated coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target for the company. One research analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $215.40.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.16% of the company’s stock.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.